The inclusion of patient-reported outcomes (PROs) in clinical research and clinical trials for liver disease has become common use in research design. Rigorous analysis and interpretation of PRO data are critically important to patients, healthcare providers, payers, drug manufacturers, and policymakers. Over the past two decades, COR-LD has been a leader in the analysis of PRO data across a broad spectrum of liver diseases, including viral hepatitis B and C, metabolic dysfunction–associated steatohepatitis (MASH), cholestatic liver diseases, cirrhosis and its complications (such as hepatic encephalopathy and ascites), and liver transplantation.
These efforts extend beyond conventional analyses of generic, disease-specific, utility, and work productivity PRO instruments to include the development of predictive models that assess changes in PRO scores before, during, and after treatment. In addition, we have employed advanced analytic methodologies to map disease-specific PRO scores to utility measures and to translate work productivity outcomes into estimates of financial burden.